Did you attend this program in person or virtually?Here's how to received credit:
1. Log into your account at www.powerpak.com
2. Click on your name in the top right hand corner of the screen
3. Click on "My Profile"
4. Scroll down to the section labelled "CPE Monitor"
5. Enter your NABP e-Profile ID and DOB
6. Scroll to the bottom and click "Save"
7. Go back up to the top right and click on your name
8. Click on "User History" (a list of courses that you have taken will come up)
9. Under this course (Exploring the Impact of Intravenous Iron for Iron Deficiency in Heart Failure) click the "Submit to CPE Monitor" button
10. Your credit should now have been successfully submitted
Exploring the Impact of Intravenous Iron for Iron Deficiency in Heart Failure
This educational activity is intended for managed care pharmacists.
PROGRAM OVERVIEW
Iron deficiency (ID), a common comorbidity in patients with heart failure (HF), is associated with significant adverse clinical outcomes, with or without the presence of anemia. These adverse consequences include a poorer quality of life and reduced exercise capacity, a higher risk of hospitalization, and increased mortality. ID is under-recognized, despite recommendations for routine testing of ferritin and transferrin saturation (TSAT) levels in guidelines. Oral iron has significant limitations, is ineffective in HF patients, and is not recommended in HF guidelines. Conversely, intravenous iron has been well-studied in numerous clinical trials and recommended in HF guidelines. One intravenous (IV) formulation, ferric carboxymaltose (FCM), has a specific indication for the treatment of patients with HF, and it has recently been evaluated in comprehensive meta-analyses for its effects on hard clinical outcomes. Therefore, in this program, to take place at the AMCP scientific sessions in New Orleans, LA, experts in ID in HF will explain to attendees key concepts of ID pathophysiology, identify the tests for diagnosis of ID and emphasize the importance
of regular screening. Evidence with IV iron and guideline recommendations will be translated to clinical practice, illustrating the value of treating HF patients with ID with IV iron. The case will demonstrate the benefits of IV iron for HF patients with ID-making them feel better (improving their HF symptoms, exercise capacity, and
overall quality of life (QOL)) and keeping them out of the hospital. The case will align with an expert-generated algorithm published in a scientific statement on ID in HF from the Heart Failure Society of America (HFSA).
EDUCATIONAL OBJECTIVES
Upon completion of this activity, participants should be able to:
● Recognize the deleterious consequences of iron deficiency, with or
without anemia, in heart failure
● Identify the drawbacks of and ineffective treatment with oral iron
therapy for iron deficiency in heart failure patients
● Interpret evidence with intravenous iron therapy for the
treatment of iron deficiency in patients with heart failure
● Explain the algorithm in the Heart Failure Society of
America Scientific Statement for the management
of iron deficiency in heart failure
The experts presenting are:
Gregory Lewis, MD
Stormi Gale, PharmD
Rajeev Malhotra, MD, MS
This activity is supported by an independent educational grant from American Regent.
Негізгі бет 2024 AMCP CPE Symposium: Exploring the Impact of IV Iron for Iron Deficiency in Heart Failure
No video
Пікірлер